IL20 and neoplasm: In conclusion, we demonstrated that IL-20 played pivotal roles in PDAC and that the anti-IL-20 antibody 7E retarded tumor progression, inhibited fibrosis in the pancreas, downregulated PD-L1 expression, mitigated CAC, and synergized with anti-PD-1 therapy to inhibit tumor growth.